Physician profile
Lori Picco
NPI 1033129259
$2,918.21
in general payments reported to CMS, 2019-2025
31 companies · $692 in 2025
The $692 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $255 · 2021: $45.68 · 2022: $271 · 2023: $456 · 2024: $729 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.99 | 2019-2025 | |
| Astellas Pharma US INC | $303.54 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $240.64 | 2023-2025 | Nexplanon |
| Coopersurgical, INC. | $218.22 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Viiv Healthcare Company | $168.69 | 2024-2025 | Apretude |
| Myriad Women'S Health, INC. | $157.65 | 2023 | Myrisk |
| Millicent US INC | $146.79 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $145.62 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $132.22 | 2023-2025 | Myfembree |
| Pfizer INC. | $122.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.65 | 2019-2025 | |
| Renovia INC | $93.49 | 2019 | |
| Daiichi Sankyo INC. | $91.24 | 2023-2024 | Injectafer |
| Avion Pharmaceuticals | $90.64 | 2019-2020 | |
| Exeltis, USA INC. | $87.68 | 2020-2025 | Slynd |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $80.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ethicon US, LLC | $78.82 | 2025 | Enseal |
| Sage Therapeutics, LLC | $53.19 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $43.69 | 2022-2024 | Ova1 |
| Mylan Pharmaceuticals INC. | $32.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $25.03 | 2025 | Gardasil 9 |
| Dexcom, INC. | $23.60 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $21.51 | 2024 | Bd Max System, Bd Max Instrument |
| Shield Therapeutics INC | $20.52 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.10 | 2025 | Qelbree |
| Seqirus USA INC | $16.23 | 2025 | Fluad, Flucelvax |
| Mayne Pharma Commercial LLC | $15.42 | 2023 | |
| Hologic Sales and Service, LLC | $14.62 | 2019 | |
| Duchesnay USA Incorporated | $13.91 | 2019 | |
| Sanofi Pasteur INC. | $12.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Picco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.